Loading organizations...
VitalX (Inflammasense) develops the VITAL-X-PATCH, a wearable technology monitoring and analyzing real-time physiological data. This device records Autonomic Neurography (ANG), a novel vital sign, for detecting critical health conditions. It employs AI-driven biomarker analytics, offering continuous, non-invasive monitoring for applications like hemodynamic decompensation and precision sepsis detection.
The company originated from the insight that traditional vital signs are insufficient for early detection of critical illnesses. Its founders recognized a need for dynamic understanding of physiological responses in conditions like sepsis and hemorrhage. This led to developing Autonomic Neurography, translating complex autonomic nervous system activity into actionable data via wearable sensors.
InflammaSense's technology serves sectors requiring rapid, accurate physiological monitoring, including military for hemorrhage detection and medical environments for sepsis identification. The company envisions proactive health intervention informed by continuous, real-time physiological data, aiming to enhance patient outcomes and improve medical research efficiency.
VitalX (Inflammasense) has raised $250K across 1 funding round.
VitalX (Inflammasense) has raised $250K in total across 1 funding round.
VitalX (Inflammasense) has raised $250K across 1 funding round. Most recently, it raised $250K Seed in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2023 | $250K Seed | — | KittyHawk Ventures, Metagrove Ventures, Kevin Zuber | Announced |
VitalX, developed by Inflammasense, is a cutting-edge healthcare technology company specializing in continuous, real-time physiological and molecular monitoring to improve clinical outcomes. Its flagship product, the VITALX-PATCH, is a wearable device that integrates neural and molecular biomarkers to detect early signs of critical illnesses such as sepsis, enabling precision treatment and accelerated clinical trials. The company serves healthcare providers, clinical researchers, defense sectors, and corporate wellness programs by offering scalable, objective decision-support tools that enhance early detection, monitoring, and prevention of life-threatening conditions[1][2].
Inflammasense was founded in 2020 in Glendale, California, by a multidisciplinary team including Imanuel Lerman, M.D., M.S. (CEO), Rahul Singh, Ph.D. (CTO), and Troy Bu, Ph.D. (Director of Design Engineering). The idea emerged from the need to detect silent early signals of sepsis and other critical conditions that traditional monitoring often misses. Early traction came from successful development of miniaturized, almost “invisible” wearable devices that continuously record vital biological signals (ECG, respiratory rate, oxygen saturation) alongside proprietary neural signals, positioning the company for FDA clearance and clinical adoption[1][2][3].
Inflammasense rides the growing trend of personalized and precision medicine, leveraging advances in wearable biosensors and molecular diagnostics. The timing is critical as healthcare increasingly demands real-time, objective data to improve outcomes and reduce costs, especially for conditions like sepsis that require rapid intervention. Market forces such as rising chronic disease prevalence, aging populations, and digital health adoption favor technologies like VitalX. By enabling earlier detection and more precise monitoring, Inflammasense influences the broader ecosystem by pushing healthcare toward proactive, data-driven care models[1][2].
Looking ahead, Inflammasense is poised to expand FDA clearances and commercial adoption of its VITALX platform, potentially broadening into other critical illness monitoring and regenerative medicine applications. Trends such as AI integration, telemedicine, and decentralized clinical trials will shape its journey, enhancing device intelligence and reach. As healthcare systems prioritize early detection and personalized care, Inflammasense’s influence is likely to grow, driving a shift toward continuous, biomarker-driven health monitoring that could redefine clinical standards and patient outcomes[1][2].
VitalX (Inflammasense) has raised $250K in total across 1 funding round.
VitalX (Inflammasense)'s investors include KittyHawk Ventures, Metagrove Ventures, Kevin Zuber.
